质量细胞仪
生物
肾透明细胞癌
遗传异质性
肿瘤微环境
多路复用
蛋白质基因组学
计算生物学
外显子组
外显子组测序
免疫系统
癌症研究
转录组
肾细胞癌
遗传学
病理
医学
基因
突变
基因表达
表型
作者
Natalia Miheecheva,Ekaterina Postovalova,Yang Lyu,Akshaya Ramachandran,Alexander Bagaev,Viktor Svekolkin,Ilia Galkin,Vladimir Zyrin,Vladislav Maximov,Yaroslav Lozinsky,Sergey Isaev,Pavel Ovcharov,Diana Shamsutdinova,Emily H. Cheng,Krystle Nomie,Jessica H. Brown,Maria Tsiper,Ravshan Ataullakhanov,Nathan Fowler,James J. Hsieh
出处
期刊:Cell Reports
[Cell Press]
日期:2022-08-01
卷期号:40 (7): 111180-111180
被引量:39
标识
DOI:10.1016/j.celrep.2022.111180
摘要
Intratumor heterogeneity (ITH) represents a major challenge for anticancer therapies. An integrated, multidimensional, multiregional approach dissecting ITH of the clear cell renal cell carcinoma (ccRCC) tumor microenvironment (TME) is employed at the single-cell level with mass cytometry (CyTOF), multiplex immunofluorescence (MxIF), and single-nucleus RNA sequencing (snRNA-seq) and at the bulk level with whole-exome sequencing (WES), RNA-seq, and methylation profiling. Multiregional analyses reveal unexpected conservation of immune composition within each individual patient, with profound differences among patients, presenting patient-specific tumor immune microenvironment signatures despite underlying genetic heterogeneity from clonal evolution. Spatial proteogenomic TME analysis using MxIF identifies 14 distinct cellular neighborhoods and, conversely, demonstrated architectural heterogeneity among different tumor regions. Tumor-expressed cytokines are identified as key determinants of the TME and correlate with clinical outcome. Overall, this work signifies that spatial ITH occurs in ccRCC, which may drive clinical heterogeneity and warrants further interrogation to improve patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI